Clinical Experience in Adults and Children Treated with Intravenous Peramivir for 2009 Influenza A (H1N1) Under an Emergency IND Program in the United States

@article{Hernndez2011ClinicalEI,
  title={Clinical Experience in Adults and Children Treated with Intravenous Peramivir for 2009 Influenza A (H1N1) Under an Emergency IND Program in the United States},
  author={Jaime E. Hern{\'a}ndez and R. B. Adiga and R. Warwick Armstrong and Jose A. Bazan and Hector F. Bonilla and John S Bradley and Robin Henry Dretler and Michael G. Ison and Julie Mangino and Stacene R. Maroushek and Avinash K Shetty and Anna Wald and Christine Ziebold and Jenna Elder and Alan S. Hollister and William P. Sheridan},
  journal={Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America},
  year={2011},
  volume={52},
  pages={695 - 706}
}
Peramivir, an investigational intravenous neuraminidase inhibitor, was given to 31 hospitalized patients with severe viral pneumonia during the 2009 H1N1 influenza pandemic under the Emergency IND regulations. The drug was generally well tolerated and associated with recovery in most patientes. 
Use of Intravenous Peramivir in a Critically Ill Toddler With Influenza A Infection and Cardiac Involvement
TLDR
A pediatric case with influenza A myopericarditis with tamponade, where use of peramivir along with pericardial effusion drainage and steroid administration improved clinical status without any side effects of the medication is reported. Expand
Peramivir: evidence to support the use of the first approved intravenous therapy for influenza
TLDR
With the recent FDA approval of single-dose therapy for uncomplicated influenza infection, the preclinical and clinical data, to date, on peramivir are reviewed. Expand
Use of Intravenous Peramivir for Treatment of Severe Influenza A(H1N1)pdm09
TLDR
The use of peramivir merits further study in randomized controlled trials, or by use of methods such as propensity scoring and matching, to assess clinical effectiveness and safety. Expand
Outcomes and Adverse Effects With Peramivir for the Treatment of Influenza H1N1 in Critically Ill Pediatric Patients.
TLDR
In the experience with 7 pediatric patients, peramivir was well tolerated at typical durations of therapy; however, increased vigilance is warranted during prolonged courses or in patients with reasons for altered pharmacokinetics and pharmacodynamics. Expand
Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections
TLDR
Successful clinical trials and post-marketing data in pediatric populations in Japan support the safety and efficacy of peramivir in this population where administration of other antivirals might not be feasible. Expand
Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010.
  • Yon C Yu, S. Garg, +5 authors T. Uyeki
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2012
TLDR
Almost 1274 hospitalized patients received peramivir through EUA program during the pH1N1 pandemic, with estimates for the potential total number of peramvir recipients ranging from 1185 to 1490. Expand
Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients.
  • M. D. de Jong, M. Ison, +7 authors W. Sheridan
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2014
TLDR
A significant clinical benefit was not demonstrated for peramivir plus SOC compared with placebo plus SOC and the findings highlight the challenges in designing studies to evaluate influenza antiviral agents in a hospitalized setting. Expand
Clinical Effectiveness of Peramivir in Comparison with Other Neuraminidase Inhibitors in Pediatric Influenza Patients
TLDR
The results suggest that peramivir is very useful in pediatric influenza patients, and no significant difference was found for any of the other combinations of drug/disease type/age groups. Expand
Intravenous Peramivir for Treatment of Influenza in Hospitalized Patients
TLDR
This open-label trial of intravenous peramivir in subjects hospitalized predominantly with 2009 influenza A (H1N1) demonstrated that once- or twice-daily administration was associated with decreases in viral shedding and clinical improvement. Expand
Safety and Pharmacokinetics of Intravenous Zanamivir Treatment in Hospitalized Adults With Influenza: An Open-label, Multicenter, Single-Arm, Phase II Study
TLDR
Safety, pharmacokinetic and clinical outcome data support further investigation of intravenous zanamivir, a neuraminidase inhibitor suitable for treatment of hospitalized patients with severe influenza. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 59 REFERENCES
Peramivir Pharmacokinetics in Two Critically Ill Adults with 2009 H1N1 Influenza A Concurrently Receiving Continuous Renal Replacement Therapy
Study Objective. To determine the pharmacokinetics of intravenous peramivir—an investigational neuraminidase inhibitor for the treatment of 2009 H1N1 infection or nonsubtypable influenza A thought toExpand
Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus.
TLDR
Intravenous zanamivir was administered on a compassionate-use basis to a profoundly immunosuppressed pediatric patient with severe oseltamiviral-resistant novel H1N1 pneumonia, and the regimen was well tolerated and was associated with a decrease in viral burden. Expand
The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza.
On October 23 the FDA issued an Emergency Use Authorization for peramivir for the treatment of suspected or confirmed cases of 2009 H1N1 influenza. Drs. Debra Birnkrant and Edward Cox discuss theExpand
Antiviral treatment for patients hospitalized with 2009 pandemic influenza A (H1N1).
  • T. Uyeki
  • Medicine
  • The New England journal of medicine
  • 2009
TLDR
Evidence from observational studies supports the benefit of neuraminidase inhibitors and Controlled trials conducted among outpatients with uncomplicated seasonal influenza reported a reduction of approximately 1 day in the duration of illness and reduced severity when antiviral treatment was initiated within 48 hours of illness onset. Expand
Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts.
TLDR
This work describes rapid selection for the H275Y resistance mutation during therapy in 2 immunocompromised individuals at 9 and 14 days of therapy, as well as the first described case of clinically significant resistance to peramivir. Expand
Global transmission of oseltamivir-resistant influenza.
  • A. Moscona
  • Biology, Medicine
  • The New England journal of medicine
  • 2009
TLDR
This winter, the circulating strain of seasonal influenza A virus (H1N1) is resistant to the neuraminidase inhibitor oseltamivir, and the surprise element is its apparently spontaneous emergence since 2007. Expand
Peramivir clearance in continuous renal replacement therapy
TLDR
D dosage for critically ill patients requiring continuous renal replacement therapy, although peramivir is partially cleared by hemodialysis in ESRD is addressed for 2 patients with H1N1 influenza with respiratory failure, sepsis-like syndrome, and anuric acute kidney failure. Expand
Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009.
TLDR
Data suggest that the use of antiviral drugs was beneficial in hospitalized patients, especially when such therapy was initiated early, and patients seemed to benefit from antiviral therapy. Expand
Efficacy and Safety of Intravenous Peramivir for Treatment of Seasonal Influenza Virus Infection
TLDR
A single intravenous dose of peramivir is effective and well tolerated in subjects with uncomplicated seasonal influenza virus infection and significantly reduced the time to alleviation of symptoms at both 300 mg and 600 mg. Expand
Critically ill patients with 2009 influenza A(H1N1) infection in Canada.
TLDR
Critical illness due to 2009 influenza A(H1N1) in Canada occurred rapidly after hospital admission, often in young adults, and was associated with severe hypoxemia, multisystem organ failure, a requirement for prolonged mechanical ventilation, and the frequent use of rescue therapies. Expand
...
1
2
3
4
5
...